Targeting the JAK2–STAT3–UCHL3–ENO1 axis suppresses glycolysis and enhances the sensitivity to 5-FU chemotherapy in TP53-mutant colorectal cancer

Targeting the JAK2–STAT3–UCHL3–ENO1 axis suppresses glycolysis and enhances the sensitivity to 5-FU chemotherapy in TP53-mutant colorectal cancer

Approximately 60% of colorectal cancer (CRC) patients exhibit TP53 mutations, which are strongly associated with tumor progression, chemotherapy resistance, and an unfavorable prognosis. However, targeting p53 has historically been challenging, and currently, there are no approved p53-based therapeu...

Full description

Saved in:
Bibliographic Details
Main Authors: Haisong Xin, Zitong Zhao, Shichao Guo, Ruoxi Tian, Liying Ma, Yang Yang, Lianmei Zhao, Guanglin Wang, Baokun Li, Xuhua Hu, Yongmei Song, Guiying Wang
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:Acta Pharmaceutica Sinica B
Subjects:
Colorectal cancer
TP53 mutation
UCHL3
Glycolysis
Stem-like properties
Chemotherapy resistance
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383525001819
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2211383525001819

Similar Items